J Wilding

Summary

Affiliation: University of Liverpool
Country: UK

Publications

  1. doi request reprint Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin
    J P H Wilding
    Department of Obesity and Endocrinology, University Hospital Aintree, Liverpool, UK
    Diabetes Obes Metab 15:750-9. 2013
  2. doi request reprint [Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin]
    J P H Wilding
    Forschungsgruppe Diabetes und Endokrinologie, Abteilung Adipositas und Endokrinologie, Zentrum für klinische Wissenschaft, Universitätsklinik Aintree, Liverpool, UK
    Dtsch Med Wochenschr 138:S27-38. 2013
  3. doi request reprint PPAR agonists for the treatment of cardiovascular disease in patients with diabetes
    J P H Wilding
    Department of Obesity and Endocrinology, University of Liverpool, Liverpool, UK
    Diabetes Obes Metab 14:973-82. 2012
  4. doi request reprint Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial
    John P H Wilding
    University Hospital Aintree, Liverpool, United Kingdom
    Ann Intern Med 156:405-15. 2012
  5. ncbi request reprint Thiazolidinediones, insulin resistance and obesity: Finding a balance
    J Wilding
    Diabetes and Endocrinology Clinical Research Group, Department of Medicine, Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK
    Int J Clin Pract 60:1272-80. 2006
  6. ncbi request reprint A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects
    J Wilding
    Diabetes and Endocrinology Research Group, Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK
    Int J Obes Relat Metab Disord 28:1399-410. 2004
  7. ncbi request reprint Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and zucker diabetic fatty rats and effects of rosiglitazone
    X J Cai
    Diabetes and Endocrinology Research Group, Department of Medicine, University of Liverpool, Liverpool, UK
    Brain Res Mol Brain Res 77:131-7. 2000
  8. ncbi request reprint Improved glycaemic control--an unintended benefit of a nurse-led cardiovascular risk reduction clinic
    A Woodward
    The Walden Diabetes Centre, University Hospital Aintree, Liverpool, UK
    Diabet Med 22:1272-4. 2005
  9. ncbi request reprint Successful cardiovascular risk reduction in Type 2 diabetes by nurse-led care using an open clinical algorithm
    A Woodward
    University Hospital Aintree, Liverpool, UK
    Diabet Med 23:780-7. 2006
  10. doi request reprint The adipokine zinc-alpha2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity
    T Mracek
    Obesity Biology Research Unit, School of Clinical Sciences, University of Liverpool, Liverpool, UK
    Clin Endocrinol (Oxf) 72:334-41. 2010

Collaborators

Detail Information

Publications18

  1. doi request reprint Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin
    J P H Wilding
    Department of Obesity and Endocrinology, University Hospital Aintree, Liverpool, UK
    Diabetes Obes Metab 15:750-9. 2013
    ..To investigate the effect of glucokinase activator AZD1656 on glycated haemoglobin (HbA1c) as an add-on to metformin in patients with type 2 diabetes...
  2. doi request reprint [Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin]
    J P H Wilding
    Forschungsgruppe Diabetes und Endokrinologie, Abteilung Adipositas und Endokrinologie, Zentrum für klinische Wissenschaft, Universitätsklinik Aintree, Liverpool, UK
    Dtsch Med Wochenschr 138:S27-38. 2013
    ..Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2, may improve glycemic control with a lower dose of insulin and attenuate the associated weight gain in patients with inadequate control despite high doses of insulin...
  3. doi request reprint PPAR agonists for the treatment of cardiovascular disease in patients with diabetes
    J P H Wilding
    Department of Obesity and Endocrinology, University of Liverpool, Liverpool, UK
    Diabetes Obes Metab 14:973-82. 2012
    ..A phase III study, ALECARDIO, is ongoing and will establish whether improvements in laboratory test profiles translate into an improvement in cardiovascular outcomes...
  4. doi request reprint Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial
    John P H Wilding
    University Hospital Aintree, Liverpool, United Kingdom
    Ann Intern Med 156:405-15. 2012
    ..Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2, may improve glycemic control with a lower dose of insulin and attenuate the associated weight gain in patients with inadequate control despite high doses of insulin...
  5. ncbi request reprint Thiazolidinediones, insulin resistance and obesity: Finding a balance
    J Wilding
    Diabetes and Endocrinology Clinical Research Group, Department of Medicine, Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK
    Int J Clin Pract 60:1272-80. 2006
    ..Evidence is reviewed that increases in body weight associated with TZD treatment are associated with neutral effects (or even, decreases) in visceral fat, the adipose depot that is associated with central obesity...
  6. ncbi request reprint A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects
    J Wilding
    Diabetes and Endocrinology Research Group, Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK
    Int J Obes Relat Metab Disord 28:1399-410. 2004
    ..Treatment of obese subjects with topiramate has recently been associated with significant weight loss in a 6-month dose-ranging study...
  7. ncbi request reprint Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and zucker diabetic fatty rats and effects of rosiglitazone
    X J Cai
    Diabetes and Endocrinology Research Group, Department of Medicine, University of Liverpool, Liverpool, UK
    Brain Res Mol Brain Res 77:131-7. 2000
    ..Obesity-related signals that might mediate this effect have not been identified, but plasma leptin, insulin and glucose are not obviously involved...
  8. ncbi request reprint Improved glycaemic control--an unintended benefit of a nurse-led cardiovascular risk reduction clinic
    A Woodward
    The Walden Diabetes Centre, University Hospital Aintree, Liverpool, UK
    Diabet Med 22:1272-4. 2005
    ..One hundred and ten patients with Type 2 diabetes were referred into a nurse-led cardiovascular risk reduction clinic. The primary aim of the clinic was to optimize blood pressure (BP) control and address cardiovascular risk factors...
  9. ncbi request reprint Successful cardiovascular risk reduction in Type 2 diabetes by nurse-led care using an open clinical algorithm
    A Woodward
    University Hospital Aintree, Liverpool, UK
    Diabet Med 23:780-7. 2006
    ..The primary aim of the clinic was to optimize blood pressure (BP) control; secondary aims were to reduce modifiable cardiovascular risk factors...
  10. doi request reprint The adipokine zinc-alpha2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity
    T Mracek
    Obesity Biology Research Unit, School of Clinical Sciences, University of Liverpool, Liverpool, UK
    Clin Endocrinol (Oxf) 72:334-41. 2010
    ..The study also examined the association between ZAG and adiponectin expression in human adipose tissue, and whether ZAG modulates adiponectin secretion by human adipocytes...
  11. pmc Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y
    M Brown
    Department of Medicine, University of Liverpool, PO Box 147, Liverpool, L69 3GA
    Br J Pharmacol 132:1898-904. 2001
    ..The hypophagic and anti-obesity effects of sibutramine in dietary-obese Wistar rats appear not to be mediated by inhibition of ARC NPY neurones...
  12. ncbi request reprint Sleep disordered breathing--a new component of syndrome x?
    S Coughlin
    Department of Medicine, Clinical Sciences Centre, University Hospital Aintree, Longmoor Lane, Liverpool L9 7AL, UK
    Obes Rev 2:267-74. 2001
    ..Whether these changes are a consequence of the associated obesity or the SDB itself remains to be proven...
  13. ncbi request reprint Hypothalamic obesity in humans: what do we know and what can be done?
    J Pinkney
    University of Liverpool, Department of Medicine, Diabetes and Endocrinology Research Group, Clinical Sciences Centre, University Hospital Aintree, Longmoor Lane, Liverpool L9 7AL, UK
    Obes Rev 3:27-34. 2002
    ..In those who are already obese, we propose that the principal causal mechanisms in individual patients should be considered as a basis for guiding clinical management...
  14. ncbi request reprint Obesity: under-diagnosed and under-treated in hospital outpatient departments
    J Cleator
    Diabetes and Endocrinology Clinical Research Group, Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK
    Int J Obes Relat Metab Disord 26:581-4. 2002
    ..This study investigated whether medically significant obesity (body mass index > 30 kg/m2) is recognised effectively in hospital outpatient departments and how those identified as obese are subsequently managed...
  15. ncbi request reprint Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study
    I Broom
    Department of Clinical Biochemistry, University of Aberdeen and Grampian University Hospitals Trust, UK
    Int J Clin Pract 56:494-9. 2002
    ..09% vs -0.55%; p<0.0001) and waist circumference (-5.99 vs -2.60 cm; p<0.0001). Orlistat was well tolerated. Orlistat weight loss is associated with improvements in cardiovascular co-morbidities, and hence cardiovascular risk...
  16. ncbi request reprint An audit of 500 subcutaneous glucagon stimulation tests to assess growth hormone and ACTH secretion in patients with hypothalamic-pituitary disease
    K S Leong
    Diabetes Centre, Whiston Hospital, Warrington Road, Prescot, Merseyside L35 5DR, UK
    Clin Endocrinol (Oxf) 54:463-8. 2001
    ..The 240 minute sample added little additional information and could be omitted...
  17. ncbi request reprint Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial
    P M J Zelissen
    University Medical Center Utrecht, Utrecht, The Netherlands
    Diabetes Obes Metab 7:755-61. 2005
    ..The aim of this study was to evaluate the effect on body weight and safety of subcutaneously administered recombinant leptin in obese adults and to evaluate whether the timing of recombinant leptin administration influences efficacy...
  18. pmc Diabetes and sleep apnoea: a hidden epidemic?
    J Wilding
    Thorax 61:928-9. 2006